Article
Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts.
Molecular cancer therapeutics - 4 May 2022
Vidimar Vania, Park Minyoung, Stubbs Caleb K, Ingram Nana K, Qiang Wenan, Zhang Shanshan, Gursel Demirkan, Melnyk Roman A, Satchell Karla J F
Abstract excerpt
The lack of effective RAS inhibition represents a major unmet medical need in the treatment of pancreatic ductal adenocarcinoma (PDAC). Here, we investigate the anticancer activity of RRSP-DTB, an engineered biologic that cleaves the Switch I of all RAS isoforms, in KRAS-mutant PDAC cell lines and patient-derived xenografts (PDX). We first demonstrate that RRSP-DTB effectively engages RAS and impacts downstream...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.